Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study.
PURPOSE: The Belgian Precision initiative aims to implement tumor-agnostic next-generation sequencing (NGS) in patients with advanced cancer and expand genotype-matching drug availability. In the HER3 cohort, a total of eight patients were included, but none demonstrated an objective response.
PURPOSE: The Belgian Precision initiative aims to implement tumor-agnostic next-generation sequencing (NGS) in patients with advanced cancer and expand genotype-matching drug availability. In the HER3 cohort, a total of eight patients were included, but none demonstrated an objective response.
What the study was
- Study design
- Phase 2 clinical trial
- Sample size
- 45
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- JCO precision oncology
Why it surfaced
Relevant Precision oncology and genomic medicine study (promising preliminary signal) meets standard-priority threshold.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.